Navigation Links
OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
Date:7/14/2008

cers and other members of management and employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of Sonus, including their respective security holdings, is set forth in Sonus' Amendment # 1 to Form 10-K for the fiscal year ended December 31, 2007, filed with the Securities and Exchange Commission on April 29, 2008, and the Proxy Statement filed with the SEC on July 3, 2008. As of June 30, 2008, OncoGenex' directors and executive officers beneficially owned approximately 1,755,000 shares, or 14.5%, of OncoGenex' capital stock. Investors may obtain additional information regarding the interests of OncoGenex, Sonus and their respective executive officers and directors in the merger by reading the Proxy Statement for such proposed transaction.

The Proxy Statement and other relevant materials, and any other documents filed by Sonus with the SEC, may be obtained free of charge at the SEC's web site at http://www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by Sonus by directing a request to: Sonus Pharmaceuticals, Inc., 1522 217th Place SE, Suite 100, Bothell, WA 98021, Phone (425) 686-1500, Fax (425) 686-1600, Attention: Investor Relations.

CONTACT: OncoGenex Media and Investor Contact: Jason I. Spark, Porter Novelli Life Sciences, (619) 849-6005, jspark@pnlifesciences.com


'/>"/>
SOURCE OncoGenex Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. OncoGenex increases economic interest in lead cancer drug OGX-011
2. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
3. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
4. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
5. CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina
6. Epeius Biotechnologies Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma
7. Edison Pharmaceuticals Receives Commendation From the City of San Jose
8. GeneraMedix Inc. Receives Approval for Epoprostenol for Injection 1.5 mg
9. Microfluidic Systems Receives Continued Funding From the Department of Homeland Security (DHS) Toward the Commercial Production of Autonomous Airborne Pathogen Detection Systems
10. Par Pharmaceutical Receives Final Approval to Market Generic Marinol(R) CIII (Dronabinol) Capsules
11. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... (PRWEB) December 23, 2014 GMO corn ... biotechnology company, Syngenta, are in the process of being ... The consolidated case is In Re: Syngenta AG MIR ... District Court for the District of Kansas. , Management ... been handed over to U.S. District Judge John W. ...
(Date:12/24/2014)... 2014 SoundConnect’s ... to introduce cutting edge communication technology, provide ... of platform upgrades. This webinar series demonstrates ... in their quest to leverage web conferencing’s ... to SoundConnect’s Marketing Manager, Seanna Baumgartner, “Our ...
(Date:12/24/2014)... 2014 According to Ross Selinger, President of ... ITRA Global, the national office market continues to be strong, ... is evidenced by the third quarter’s surprising 3.9% GDP, unemployment ... energy costs have held inflation down and the Fed is ... housing market remaining soft. , This solid economic news is ...
(Date:12/24/2014)... Nashville Fertility Center announced that Dr. ... American Society for Reproductive Medicine (ASRM), a leading professional ... medicine. In his new role as treasurer, Dr. ... and will have a voice in furthering the mission ... ASRM since 1984 when he joined while conducting fellowship ...
Breaking Biology Technology:Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3
... - Strong Sales Growth Across All Product Lines ... Sales Growth ... IRVINE, Calif., April 22 Edwards Lifesciences,Corporation (NYSE: EW ... disease, today reported net income for the,quarter ended March 31, 2008 ...
... Trust, Inc.,(NYSE: BMR ) today announced that ... additional shares of common stock in,connection with BioMed,s ... 2008. In total, the company sold 6,129,000 shares ... $156.3,million., The underwriters for the offering are ...
... Calif., April 22 Microchip Biotechnologies,Inc. (MBI) ... multi-patent license,agreement with GE Healthcare that significantly ... of lab-on-a-chip devices. The,patents cover design and ... "Licensing these fundamental patents continues to build ...
Cached Biology Technology:Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 2Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 3Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 4Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 5Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 6Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 7Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 8Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 9Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 10Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 11Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 12Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 13Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance 14BioMed Realty Trust Announces Exercise of Over-Allotment Option for Common Stock 2BioMed Realty Trust Announces Exercise of Over-Allotment Option for Common Stock 3Microchip Biotechnologies, Inc. Enters Into License Arrangement With GE Healthcare for Fundamental Microfluidic Patents 2
(Date:12/17/2014)... 2014 Research and Markets ( ... "Samsung Galaxy S5 - Home Button Synaptics ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... technology than the iPhone 5S, Samsung introduces for ... product. The Galaxy S5 home button ...
(Date:12/17/2014)... NEW YORK , Dec. 15, 2014 /PRNewswire-USNewswire/ ... a Good Clinical Practices (GCP) audit to confirm ... Administration (FDA) regulations. This accomplishment enables HITLAB to ... trials utilizing the highest principles for patient safety ... to improve global healthcare access, quality, and delivery ...
(Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) ... Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this ... in biomedical applications. Chemical sensors help in recording ... during surgical procedures. The Global Chemical Sensor market ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... Such Board on the Market, Stantum,s SMK Series ... Own Resistive Multi-Touch Applications, SAN DIEGO, Sept. ... developer of multi-touch sensing,technology, today introduced a demo, ... resistive multi-touch technology, which lets,users simultaneously move an ...
... been awarded $1 million from the US Department of ... conversion technologies. The grant is one of six awarded ... their advanced biofuels projects. In total, the DOE will ... for their research into how non-food feedstocks can be ...
... skin disorder called vitiligo, which causes unsightly white patches on ... A Loyola University Hospital researcher has won a five-year, $1.7 ... vitiligo. This research also could point the way to new ... Vitiligo appears to be an auto-immune disease, in which the ...
Cached Biology News:Stantum Offering Demo, Evaluation & Development Board Based on Its Patented Resistive Multi-Touch Technology 2Stevens awarded $1M for advanced biofuels research 2Vitiligo skin disorder could yield clues in fight against melanoma 2
Intestinal Epithelium Differentiation Environment...
... provides a familiar interface for data ... warehousing. The transition from paper to ... LABTrack contains an integrated LIMS, ... rules mechanism. These functions allow LABTrack ...
Mouse monoclonal [M2II-12] to MRP2 ( Abpromise for all tested applications). entrezGeneID: 1244 SwissProtID: Q92887...
Rab GDP dissociation inhibitor beta...
Biology Products: